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Abstract
Background: In the population a high body mass index (BMI) has been associated with slightly increased inflammatory
markers. Within rheumatoid arthritis (RA), however, a high BMI has been associated with less radiographic progression;
this phenomenon is unexplained. We hypothesized that the phenomenon is caused by an inverse relationship
between BMI and inflammation in hand and foot joints with RA. To explore this hypothesis, local inflammation
was measured using magnetic resonance imaging (MRI) in early arthritis patients presenting with RA or other
arthritides and in asymptomatic volunteers.
Methods: A total of 195 RA patients, 159 patients with other inflammatory arthritides included in the Leiden Early
Arthritis Clinic, and 193 asymptomatic volunteers underwent a unilateral contrast-enhanced 1.5 T MRI scan of
metacarpophalangeal, wrist, and metatarsophalangeal joints. Each MRI scan was scored by two readers on
synovitis, bone marrow edema (BME), and tenosynovitis; the sum yielded the total MRI inflammation score. Linear
regression on log-transformed MRI data was used.
Results: A higher BMI was associated with higher MRI inflammation scores in arthritides other than RA (β = 1.082,
p < 0.001) and in asymptomatic volunteers (β = 1.029, p = 0.040), whereas it was associated with lower MRI inflammation
scores in RA (β = 0.97, p= 0.005). Evaluating the different types of inflammation, a higher BMI was associated with higher
synovitis, BME, and tenosynovitis scores in arthritides other than RA (respectively β = 1.084, p < 0.001, β = 1.021, p = 0.24,
and β = 1.054, p = 0.003), but with lower synovitis and BME scores in RA (respectively β = 0.98, p = 0.047 and β = 0.95,
p = 0.002).
Conclusions: Increased BMI is correlated with less severe MRI-detected synovitis and BME in RA. This might explain the
paradox in RA where obesity correlates with less severe radiographic progression.
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Background
The prevalence of obesity is increasing worldwide. It has
become evident that adipose tissue is an active organ,
producing proinflammatory cytokines and adipocyto-
kines. A population-based study has shown that a high
body mass index (BMI) is associated with increased
inflammatory markers, such as C-reactive protein (CRP)
[1]. Obesity is also associated with an increased risk for
several diseases, among which is cardiovascular disease,
in which low-grade inflammation is part of the patho-
genesis. Furthermore, recent data have revealed that
obesity is also associated with an increased risk for
rheumatoid arthritis (RA) [2].
Interestingly, however, although obese persons have a
higher risk to develop RA, the presence of obesity within
RA has been shown advantageous. Several studies have
observed and replicated that a higher BMI is associated
with less severe radiographic joint progression in RA
[3–6]. The mechanisms underlying this observation are
unknown. Data from a recent clinical trial in RA, evalu-
ating drug efficacy with magnetic resonance imaging
(MRI) to measure the disease outcome, suggested that
patients with a higher BMI have less severe bone mar-
row edema (BME) on MRI [3]. BME is strongly associ-
ated with erosive progression [7], which may explain the
finding of BMI and radiographic progression in RA.
Together these observations prompted us to study the
association between BMI and MRI-detected joint inflam-
mation in more detail.
This cross-sectional study investigated the association
between BMI and inflammation in hand and foot joints
detected by MRI at disease presentation; we hypothe-
sized that a higher BMI is associated with less severe
local inflammation in RA. Because an advantageous
effect of BMI has only been observed thus far in RA, we
also evaluated the association between BMI and MRI-
detected inflammation differed in RA patients compared




Three groups were studied. Firstly, RA patients who
were consecutively included in the Leiden Early Arthritis
Clinic (EAC) cohort between August 2010 and October
2014. Secondly, early arthritis patients with other inflam-
matory diagnoses who were included in the same cohort
in the same time period. Thirdly, asymptomatic volun-
teers who were recruited from the general population.
The EAC cohort is an inception cohort of early arth-
ritis patients presenting with clinically detected arthritis
of ≥ 1 joint and symptom duration < 2 years [8]. At base-
line, questionnaires were filled, physical examination was
performed (including weight and height), blood samples
were obtained, and MRI was performed. RA was defined
as fulfilling the 1987 ACR criteria during the first year of
follow-up.
The asymptomatic volunteers were recruited between
November 2013 and December 2014 [9]. Volunteers
were recruited via advertisements in local newspapers
and websites. The volunteers had no history of RA or
other inflammatory rheumatic diseases, no joint symp-
toms during the last month, and no clinically detectable
arthritis at physical examination. Participants received a
voucher of €20 to compensate for their time and travel
costs and did not receive a report of the MRI results.
Therefore, volunteers had no/limited benefit from
participating.
MRI protocol and scoring
On an ONI-MSK-extreme 1.5 T extremity MRI machine
(General Electric, WI, USA), imaging was performed of
the unilateral metacarpophalangeal (MCP) 2–5 joints,
wrist joints, and metatarsophalangeal (MTP) 1–5 joints.
In patients the most painful side was scanned or, in case
of equally severe symptoms on both sides, the dominant
side. In asymptomatic volunteers, the dominant side was
scanned. According to the protocol, the MRI scan was
performed before the 2-week visit in which patients re-
ceive their diagnosis, and the median time between the
first visit and the MRI scan was 8 days. Furthermore,
patients were asked to stop NSAIDS 24 hours prior to
the MRI scan. The following sequences were acquired:
T1 fast-spin echo (T1), T2-weighted fat saturated (T2),
and, after intravenous contrast administration (gadoteric
acid, 0.1 mmol/kg; Guerbet, Paris, France), T1 fast-spin
echo with fat saturation (T1 Gd). A detailed scan proto-
col is provided in Additional file 1. Scoring was carried
out according to the RAMRIS for synovitis and BME in
the MCP, wrist, and MTP joints and according to Haa-
vardsholm et al. for tenosynovitis in the MCP and wrist
[10, 11]. The total MRI inflammation score was calcu-
lated by summing the synovitis, BME, and tenosynovitis
scores. MRI scoring of the arthritis patients was done
independently by two trained readers (WPN and ECN)
and the asymptomatic volunteers were scored independ-
ently by two trained readers (HWvS and LM). All
readers were trained before the start of this project.
Readers were blinded for any clinical data. MRI images
of asymptomatic volunteers were blinded and mixed
with MRI images of RA patients and patients with arth-
ralgia without clinical synovitis (n = 99), to exclude
observer bias scoring introduced by knowledge that per-
sons had no symptoms. The within-reader intraclass cor-
relation coefficients (ICC) for the readers who scored
the arthritis patients were 0.98 and 0.93, and for the
readers who scored the asymptomatic volunteers these
were 0.98 and 0.99. The between-reader ICC of the four
Mangnus et al. Arthritis Research & Therapy  (2016) 18:245 Page 2 of 8
readers were all above 0.91 (Additional file 2). The mean
scores of two readers were used for the analyses.
Analyses
Associations between MRI-detected inflammation and
BMI were assessed using univariable and multivariable
linear regression analyses. The MRI inflammation scores
were log10-transformed (log10(score + 1)) to approximate a
normal distribution. Thereafter, BMI was divided into three
categories according to the World Health Organization
(WHO) definition: low-normal weight (< 25 kg/m2), over-
weight (≥ 25 to < 30 kg/m2), and obese (≥ 30 kg/m2). The
Kruskal–Wallis test, Mann–Whitney U test, linear regres-
sion models, and Spearman rank correlation coefficient
were used as appropriate. SPSS V23.0.0 was used.
In RA patients treated in a trial, an association
between BMI and BME was observed [3]. We sought to
compare our findings in an unselected RA population at
disease presentation with these results. In order to do
so, we performed a multivariable ordinal logistic regres-
sion model in which BME was categorized into quintiles,
similar to that done in the trial [3].
Results
Participants
In total, 202 RA patients and 170 early arthritis patients
with other inflammatory diagnoses were consecutively
included in the Leiden EAC. Five RA patients and eight
other arthritis patients had no information on height or
weight and, respectively, two and three patients had an
MRI scan without contrast enhancement and were ex-
cluded. Therefore, 195 RA patients and 159 arthritis
patients with other inflammatory diagnoses were evalu-
ated. In addition, 196 asymptomatic volunteers were
recruited, as already described, three of whom did not
receive an MRI scan due to personal problems (n = 1),
vasovagal collapse at intravenous puncture (n = 1), and
anxiety (n = 1).
Baseline characteristics of all participants are pre-
sented in Table 1. Seventy-nine (41 %) RA patients were
overweight (BMI > 25 to < 30 kg/m2) and 41 (21 %) were
obese (≥ 30 kg/m2); in other arthritis patients these
percentages were respectively 44 % (n = 70) and 14 %
(n = 23), and in asymptomatic volunteers these percent-
ages were 32 % (n = 61) and 9 % (n = 17) respectively.
BMI and MRI-detected inflammation
The median MRI inflammation score in RA patients was
14.5 (IQR = 7.0–26.5), in other arthritis patients the me-
dian was 6.0 (IQR = 2.0–15.0), and in asymptomatic vol-
unteers the median was 2.0 (IQR = 0.5–4.5, p < 0.001),
showing that RA patients had the highest MRI inflam-
mation scores.
In RA patients, a higher BMI was associated with
lower MRI inflammation scores (β = 0.97, p = 0.024). A β
value of 0.97 indicates that for every point increase in
BMI there is a 0.97-fold increase in MRI inflammation
score; thus higher BMI was associated with less severe
MRI inflammation. In contrast, in other arthritis patients
and in asymptomatic volunteers, a higher BMI was asso-
ciated with higher MRI inflammation scores (respect-
ively β = 1.082, p < 0.001 and β = 1.029, p = 0.040; Fig. 1).
When BMI was categorized into three groups (low-nor-
mal weight, overweight, and obese), similar results were
Table 1 Characteristics of early rheumatoid arthritis patients, early arthritis patients with other arthritides, and asymptomatic volunteers
Rheumatoid arthritis
(n = 195)




Female, n (%) 119 (66) 80 (52) 136 (70)
Age, mean (SD) 55.9 (14.6) 54.3 (17.2) 50.7 (26.4)
Symptom duration (months), median (IQR) 3.2 (1.8–6.8) 3.0 (1.0–6.2) –
Current smokers, n (%) 38 (24) 29 (23) 17 (9)
BMI (kg/m2), median (IQR) 26.4 (23.7–29.4) 25.5 (22.9–27.9) 24.1 (22.3–26.3)
WHO BMI classification, n (%)
Low-normal weight (BMI 18.5–24.9 kg/m2) (%) 75 (38) 66 (42) 115 (60)
Overweight (BMI 25.0–29.9 kg/m2) (%) 79 (41) 70 (44) 61 (32)
Obesity (BMI ≥ 30 kg/m2) (%) 41 (21) 23 (14) 17 (9)
CRP (mg/L), median (IQR) 9.8 (3.7–23.0) 4.0 (3.0–15.1) NA
ACPA positivity, n (%) 107 (55) 6 (4) NA
RF positivity, n (%) 120 (62) 27 (17) NA
Three (2 %) RA patients had a low weight (BMI <18.5 kg/m2), no patients with other arthritides had a low weight, and two (1 %) asymptomatic volunteers had a
low weight
Gender was missing in 11 RA patients; within early arthritis patients with other arthritides, gender, ACPA positivity and RF positivity was missing in respectively six,
two, and three patients
NA not assessed, WHO World Health Organization, BMI body mass index, CRP C-reactive protein, ACPA anti-citrullinated protein antibody, RF rheumatoid factor,
RA rheumatoid arthritis
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obtained. Obese RA patients had significantly lower
MRI inflammation scores (median = 10.0, IQR = 6.5–
18.0) compared with low-normal weight RA patients
(median = 19.5, IQR = 7.5–29.0, p = 0.005) and over-
weight RA patients (median = 14.5, IQR = 7.0–28.0, p =
0.046). Within the group of other early arthritis
patients, obese patients had higher total MRI inflam-
mation scores (median = 8.5, IQR = 5.0–13.5) compared
with patients with a low-normal weight (median = 2.5,
IQR = 0.5–9.5, p = 0.002). Similarly, overweight was
also associated with higher total MRI inflammation
scores (median = 8.0, IQR = 3.5–22.0, p < 0.001). Within
asymptomatic volunteers a tendency towards higher
inflammation scores was seen in obese persons
(median = 3.5, IQR = 1.0–5.5) compared with low-
normal weight persons (median = 1.5, IQR = 0.5–3.5, p =
0.064) and overweight persons (median = 2.0, IQR =
1.0–4.5, p = 0.24; Fig. 1).
Fig. 1 Association between BMI (both when presented on a continuous scale and when categorized) and MRI-detected inflammation is different
in early RA patients (a) compared with early arthritis patients with other diagnoses (b) and asymptomatic volunteers (c). Total inflammation scores
were log-transformed for regressions. Regression coefficients presented are back-transformed (10β and 1095 % CI). In RA patients the back-transformed
regression coefficient is 0.97 (95 % CI 0.94–1.00, a left), in arthritis patients with other diagnoses the coefficient is 1.082 (95 % CI 1.041–1.13, b left), and
in asymptomatic volunteers it was 1.029 (95 % CI 1.001–1.057, c left). Horizontal lines (right) represent median values. BMI body mass index
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Thereafter, the association between BMI (measured
continuously) and MRI-detected inflammation was ad-
justed for age and gender, also showing that a higher
BMI was associated with higher inflammation scores in
other early arthritis patients (β = 1.036, p = 0.054) and
asymptomatic volunteers (β = 1.022, p = 0.040) but with
lower inflammation scores in RA patients (β = 0.96, p =
0.005; Table 2 (for nonback-transformed β values, see
Additional file 3)). After additional adjustments for
CRP and anti-citrullinated protein antibody (ACPA) the
results remained similar (β = 0.96, p = 0.003 for RA
patients and β = 1.039, p = 0.043 for other early arthritis
patients).
The group of early arthritis patients with diagnoses
other than RA was divided into the following six sub-
groups: inflammatory osteoarthritis (n = 38), spondy-
loarthritis with peripheral arthritis and psoriatic
arthritis (n = 40), systemic lupus erythematosus/mixed
connective tissue disease and other systemic disease
(n = 20), reactive arthritis and lyme arthritis (n = 17),
gout and pseudogout (n = 19), and other diseases (n = 25).
These subgroups were studied to assess whether the asso-
ciation was more pronounced in a particular disease
group. However, the directionality of the effect was similar
in all subgroups (Additional file 4).
BMI and different types of MRI inflammation
The total MRI inflammation score is composed of the
synovitis, tenosynovitis, and BME scores. To assess
whether synovitis, BME, and tenosynovitis have different
associations with BMI, these types of inflammation were
assessed separately. The synovitis score showed a nega-
tive association with BMI in RA patients (β = 0.98, p =
0.047) and a positive association in other arthritis
patients and in asymptomatic volunteers (β = 1.084, p <
0.001 and β = 1.031, p = 0.006 respectively). A higher
BMI was associated with lower BME in RA patients (β =
0.95, p = 0.002). In other arthritis patients and in asymp-
tomatic volunteers, BMI was not associated with BME
scores (respectively β = 1.021, p = 0.24 and β = 1.003, p =
0.79). Within other arthritis patients and in asymptom-
atic volunteers there was a positive association between
BMI and the tenosynovitis score (β = 1.054, p = 0.003
and β = 1.021, p = 0.003 respectively), whereas BMI was
not associated with tenosynovitis in RA (β = 0.98, p =
0.21; Additional file 5).
Further analyses in BMI and BME
Recently, an inverse association between BMI and BME
was shown in RA patients who were treated in a trial
[3]. The median BME scores of patients included in this
trial and who were low-normal weight, overweight, and
obese patients were respectively 9 (IQR 2.5–19), 6.3
(IQR 2.5–13), and 4.8 (IQR 1.5–9.8) [3]. We wished to
compare these recent results with our findings obtained
in an unselected set of RA patients at the time of disease
onset. The median scores observed in our cohort
showed a similar tendency but were lower; the median
scores in the three groups were respectively 5.0 (IQR
2.0–11.0), 3.0 (IQR 1.0–9.0), and 2.0 (IQR 1.0–4.5). The
Table 2 Association of BMI with MRI-detected inflammation in patients with RA, early arthritis patients with other arthritides, and
asymptomatic volunteers
Rheumatoid arthritis (n = 195) Other arthritides (n = 159) Asymptomatic volunteers (n = 193)
β (95 % CI) p value β (95 % CI) p value β (95 % CI) p value
Univariable
BMI 0.97 (0.94–1.00) 0.024 1.082 (1.041–1.13) <0.001 1.029 (1.001–1.057) 0.040
Multivariable
Model 1
BMI 0.96 (0.94–0.99) 0.005 1.036 (1.00–1.075) 0.054 1.022 (1.001–1.044) 0.040
Age 1.025 (1.017–1.033) < 0.001 1.033 (1.024–1.041) < 0.001 1.031 (1.025–1.036) < 0.001
Gender 1.13 (0.89–1.44) 0.30 0.88 (0.67–1.15) 0.34 1.010 (0.84–1.21) 0.92
Model 2
BMI 0.96 (0.94–0.99) 0.003 1.039 (1.001–1.078) 0.043 NA
Age 1.022 (1.014–1.030) < 0.001 1.030 (1.021–1.039) < 0.001 NA
Gender 1.12 (0.89–1.41) 0.35 0.93 (0.71–1.23) 0.62 NA
CRP 1.007 (1.003–1.012) 0.001 1.002 (0.998–1.006) 0.29 NA
ACPA positivity 0.96 (0.77–1.20) 0.72 1.55 (0.75–3.20) 0.24 NA
Total inflammation scores were log-transformed for regressions. Regression coefficients presented are back-transformed (10β and 1095 % CI). Therefore, the effect
size (β) can be interpreted as the fold increase in MRI-detected inflammation per point increase in BMI. Thus, an effect size of < 1 means a decrease in MRI-detected
inflammation per unit increase in BMI and an effect size of > 1 means an increase in MRI-detected inflammation per unit increase in BMI. The raw beta coefficients are
presented in Additional file 3
BMI body mass index, MRI magnetic resonance imaging, RA rheumatoid arthritis, NA not assessed, CRP C-reactive protein, ACPA anti-citrullinated protein antibody
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trial data showed that, after adjusting for race, ACPA,
disease duration, DAS, age, and sex, overweight
patients had an odds ratio (OR) of 0.68 (95 % CI 0.42–
1.08, p = 0.1) and obese patients an OR of 0.47 (95 % CI
0.27–0.82, p = 0.008) for being in a higher BME quintile
(Fig. 2). We performed the same analyses without
adjusting for race because our study population con-
sisted of 96 % Caucasians, and without disease duration
because all of our early arthritis patients were evaluated
at their first presentation to the rheumatologic out-
patient clinics. In our data, overweight patients had an
OR of 0.42 (95 % CI 0.23–0.79, p = 0.007) and obese pa-
tients had an OR of 0.30 (95 % CI 0.14–0.64, p = 0.002)
compared with low-normal weight patients (Fig. 2).
Analyses of both data sets thus showed an inverse asso-
ciation between BMI and BME scores.
BMI and regular measures of inflammation
The association of BMI with regular measures of inflam-
mation was assessed in RA patients and other arthritis
patients. In RA patients the median swollen joint count
(SJC) in low-normal weight patients was 5 (IQR = 3–10),
in overweight patients the median was 6 (IQR = 2–10),
and in obese patients the median was 8 (IQR = 3–10;
p = 0.69). The median CRP levels in low-normal
weight, overweight, and obese RA patients were respect-
ively 7 mg/L (IQR = 3–23 mg/L), 12 mg/L (IQR = 4–
23 mg/L), and 10 mg/L (IQR = 4–24 mg/L; p = 0.39). In
other arthritis patients the median of SJC in low-normal
weight, overweight, and obese patients were respectively 3
(IQR = 1–5), 3 (IQR = 2–5), and 4 (IQR = 3–7; p = 0.074).
Lastly, the median CRP level in the three groups were
respectively 4 mg/L (IQR = 3–18 mg/L), 4 mg/L (IQR =
3–12 mg/L), and 5 mg/L (IQR = 3–13 mg/L; p = 0.65).
Therefore, in RA patients and in other arthritis patients,
BMI was neither associated with swollen SJC nor with
CRP levels.
BMI and ACPA in RA patients
The influence of BMI on MRI-detected inflammation in
ACPA-positive or ACPA-negative RA patients was
assessed separately. Although the subgroups became
small (n = 107 and n = 88 respectively), the effect size of
the association between BMI and MRI-detected inflam-
mation remained unchanged (respectively β = 0.97, p =
0.071 and β = 0.97, p = 0.12 for ACPA-positive RA and
ACPA-negative RA in the univariable analyses and re-
spectively β = 0.97, p = 0.097 and β = 0.96, p = 0.011 for
the analyses adjusted for age and gender).
Furthermore, the association between ACPA level and
BMI was assessed with the Spearman rank test in all RA
patients. ACPA levels were not correlated with BMI (ρ =
−0.33, p = 0.65) and did not differ between the three
BMI categories (p = 0.38; Additional file 6).
Discussion
An increased BMI is associated with higher inflamma-
tory markers in the general population [1], and a higher
risk for RA development [2]. A high BMI within RA,
however, is associated with less severe radiographic joint
damage [3–6]. Because joint destruction is the result of
persistent inflammation, the present cross-sectional
study assessed the association between BMI and MRI-
detected inflammation and showed that RA patients
with a high BMI had less MRI-detected inflammation.
More specifically, patients had less severe synovitis and
BME. This inverse association was not observed in early
arthritis patients with other inflammatory diagnoses and
in asymptomatic volunteers. This suggests that the
inverse association between BMI and local joint inflam-
mation is confined to RA and may explain the previously
reported observation of less severe radiographic progres-
sion in obese RA patients.
The mechanism underlying this inverse association is
unknown. It can be speculated that adipocytokines play
a role. It could be that the composition of the adipocy-
tokines is different between various diseases; for
example, the balance between low molecular weight
versus high molecular weight adiponectin might be
different. Another possibility is that the interaction be-
tween adipocytokines and immune cells is different
within RA compared with other diseases. However, we
have no data to support these speculations and further
studies are needed to unravel the biologic mechanism
underlying our observation.
To the best of our knowledge RA is the only disease
in which obese patients have less severe inflammation
and progression. Also, the effect of obesity for RA is
two-fold. Despite the association with less severe MRI-
Fig. 2 Association of overweight and obesity with BME compared
with low-normal weight in RA patients included in the EAC cohort
and the GO-BEFORE trial [3]. BMI was categorized into three groups:
low-normal weight (< 25 kg/m2), overweight (≥ 25 to < 30 kg/m2),
and obese (≥ 30 kg/m2). Odds ratios (ORs) were calculated with low/
normal weight as the reference category. EAC Early Arthritis Clinic
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detected inflammation and less severe radiographic
progression, obesity has been associated with a higher
risk for developing RA and a lower risk for reaching
persistent remission [2, 12]. Furthermore, a lower
chance to achieve a low disease activity has also been
observed in RA patients that use synthetic DMARDs
and biological DMARDs [13–15]. Of note, when evalu-
ating the components of the disease activity score, the
effect was only present for subjective measures (tender
joint count and patient global assessment) and not for
objective measures of inflammation (CRP, erythrocyte
sedimentation rate, and swollen joint count) [13].
Also in the present study we observed no association
between BMI and either the CRP levels or the number
of swollen joints. This illustrates that local inflammation
is different from systemic inflammation and also under-
lines that MRI is a more sensitive method to detect local
inflammation than physical examination of joints.
Apparently the less severe radiographic progression in
RA is paralleled by less severe local inflammation, which
is detected when local inflammation is measured using a
sensitive method. As such, the results of the present
study suggest that MRI is not only valuable as an out-
come measure in clinical trials but that MRI studies may
also help to increase our pathophysiological understand-
ing of RA.
In line with recommendations of the ESSR [16], BME
was evaluated on T1 Gd, which is different from the
RAMRIS methodology using T2. Our scan protocol
omitted T2 because previous studies have shown that
these sequences perform equally well in the depiction of
BME [17, 18] and the T1 Gd sequence allows a shorter
imaging time for the patients. The present finding of
similar effects of BMI in BME as observed in two differ-
ent studies in which BME was assessed on different
sequences (Baker et al. [3] used short tau inversion
recovery (or T2 precontrast) sequences) support the
notion that the findings are not influenced by the se-
quence used to depict BME.
This study has limitations. The BMI was used as an
estimate of the adipose tissue, but differences in BMI are
not only caused by differences in adipose tissue but also
by differences in, for instance, muscle mass. There are
methods that could make more accurate estimations in
this respect, such as waist circumference, bioelectrical
impedance, or computed tomography. Another im-
portant limitation is that long-term follow-up was not
yet available for the RA patients who had undergone
MRI. Therefore we could not assess whether our find-
ings at disease presentation might explain the associ-
ation of BMI with less severe radiographic joint
progression. In addition we could not determine the
association of BMI with other disease outcomes, such
as persistent remission.
Conclusions
The association between BMI and MRI-detected inflam-
mation differs in patients with RA compared with pa-
tients with other inflammatory diagnoses and with
asymptomatic controls. Within RA a higher BMI is asso-
ciated with less severe MRI-detected inflammation, and
this may explain the finding that obese RA patients have
less severe radiographic progression.
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